Literature DB >> 11950489

Synergistic inhibitory effects of genistein and tamoxifen on human dysplastic and malignant epithelial breast cells in vitro.

Vasilios Tanos1, Amnon Brzezinski, Olga Drize, Nurith Strauss, Tamar Peretz.   

Abstract

OBJECTIVE: Genistein is a phytoestrogen with in vitro anticancerogenic activity. We examined in vitro the effects of genistein alone, or in combination with estradiol and tamoxifen, on the growth of human dysplastic and malignant epithelial breast cell lines.
METHODS: Dysplastic breast cell lines (MCF-10A(1), MCF-ANeoT, MCF-T(6)3B) and cell lines of breast cancer (MCF-7, MDA-231, MDA-435) were cultured as monolayers in RPMI 1640 medium supplemented with 10% fetal bovine serum, and L-glutamine. After preincubation of 20 h, genistein (1, 2.5, 5, 7.5 and 10 microg/ml) alone or in combination with estrogen or tamoxifen was added to the cultured cells. The cells were treated continuously for 72 h and then the growth rate was assessed colorimetrically. Stepwise multiple linear regression analysis was used to evaluate the effect of genistein, tamoxifen, and estradiol on cell proliferation.
RESULTS: Genistein had a significant (dose-dependent) inhibitory effect on the proliferation of both dysplastic (P<0.0001) and malignant (P<0.0001) cells. The growth inhibition was significantly higher P<0.0001 in dysplastic cells compared to the cancer cells. Addition of tamoxifen to genistein further inhibited the proliferation of both cell types, reflecting a synergistic antiproliferative effect on dysplastic cells P<0.0001 and an additive growth inhibition effect P<0.0003 on malignant cells. Estradiol significantly (P=0.005) stimulated the growth of dysplastic cell lines while a significant (P=0.003) antiproliferative effect on growth of the malignant cells was observed. The concentration of estrogen receptor (ER) had no significant effect on growth rates and did not modulate the effects of genistein or tamoxifen.
CONCLUSIONS: Genistein (1-10 microg/ml) inhibits the growth of dysplastic and malignant epithelial breast cancer cells in vitro and the addition of tamoxifen (10(-6), 10(-7)M) has a synergistic/additive inhibitory effect. These effects are not modulated by the presence of ER.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11950489     DOI: 10.1016/s0301-2115(01)00582-6

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  14 in total

1.  Soy food intake after diagnosis of breast cancer and survival: an in-depth analysis of combined evidence from cohort studies of US and Chinese women.

Authors:  Sarah J Nechuta; Bette J Caan; Wendy Y Chen; Wei Lu; Zhi Chen; Marilyn L Kwan; Shirley W Flatt; Ying Zheng; Wei Zheng; John P Pierce; Xiao Ou Shu
Journal:  Am J Clin Nutr       Date:  2012-05-30       Impact factor: 7.045

2.  Low-dose dietary genistein negates the therapeutic effect of tamoxifen in athymic nude mice.

Authors:  Mengyuan Du; Xujuan Yang; James A Hartman; Paul S Cooke; Daniel R Doerge; Young H Ju; William G Helferich
Journal:  Carcinogenesis       Date:  2012-01-20       Impact factor: 4.944

3.  Soy food intake and breast cancer survival.

Authors:  Xiao Ou Shu; Ying Zheng; Hui Cai; Kai Gu; Zhi Chen; Wei Zheng; Wei Lu
Journal:  JAMA       Date:  2009-12-09       Impact factor: 56.272

4.  Genistein inhibit cytokines or growth factor-induced proliferation and transformation phenotype in fibroblast-like synoviocytes of rheumatoid arthritis.

Authors:  Yujun Zhang; Jianqiang Dong; Peiying He; Wende Li; Qi Zhang; Na Li; Tiezheng Sun
Journal:  Inflammation       Date:  2012-02       Impact factor: 4.092

5.  Potential beneficial metabolic interactions between tamoxifen and isoflavones via cytochrome P450-mediated pathways in female rat liver microsomes.

Authors:  Jun Chen; Steven C Halls; Joshua F Alfaro; Zhaohui Zhou; Ming Hu
Journal:  Pharm Res       Date:  2004-11       Impact factor: 4.200

6.  Soy phytochemicals synergistically enhance the preventive effect of tamoxifen on the growth of estrogen-dependent human breast carcinoma in mice.

Authors:  Zhiming Mai; George L Blackburn; Jin-Rong Zhou
Journal:  Carcinogenesis       Date:  2007-01-18       Impact factor: 4.944

Review 7.  Multi-targeted therapy of cancer by genistein.

Authors:  Sanjeev Banerjee; Yiwei Li; Zhiwei Wang; Fazlul H Sarkar
Journal:  Cancer Lett       Date:  2008-05-19       Impact factor: 8.679

8.  Comparative effects of estradiol, methyl-piperidino-pyrazole, raloxifene, and ICI 182 780 on gene expression in the murine uterus.

Authors:  Angela M Davis; Jiude Mao; Bushra Naz; Jessica A Kohl; Cheryl S Rosenfeld
Journal:  J Mol Endocrinol       Date:  2008-07-16       Impact factor: 5.098

9.  A new role for tamoxifen in oestrogen receptor-negative breast cancer when it is combined with epigallocatechin gallate.

Authors:  M J Scandlyn; E C Stuart; T J Somers-Edgar; A R Menzies; R J Rosengren
Journal:  Br J Cancer       Date:  2008-09-16       Impact factor: 7.640

10.  Tamoxifen ameliorates peritoneal membrane damage by blocking mesothelial to mesenchymal transition in peritoneal dialysis.

Authors:  Jesús Loureiro; Pilar Sandoval; Gloria del Peso; Guadalupe Gónzalez-Mateo; Vanessa Fernández-Millara; Beatríz Santamaria; Maria Auxiliadora Bajo; José Antonio Sánchez-Tomero; Gonzalo Guerra-Azcona; Rafael Selgas; Manuel López-Cabrera; Abelardo I Aguilera
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.